Category: Allies & Partnerships
Painting a Portrait of the Melanoma Clinical Trial Participant
MRA Chief Science Officer Marc Hurlbert, MRA Director of Communications Cody Barnett, and Antidote's Head of Partnerships Lindsey Wahlstrom-Edwards discuss what matters most to melanoma patients when it comes to participating in clinical trials.
Maintaining Momentum in Melanoma Research
The last decade has been one of substantial progress and hope for many melanoma patients, researchers, and clinicians. With 12 new therapeutic approaches now approved to treat melanoma, many advanced-stage patients are seeing their tumors shrink or disappear, and are experiencing renewed hope for a brighter future.
Facing Melanoma Together
Measuring the progress of melanoma research through numbers isn’t hard. What’s harder to quantify – or to even put into words – is the individual impact that this research makes in the lives of patients and their loved ones. It's this human impact that Facing Melanoma Together, a series of black and white photographs, helps bring to the forefront.
Lighting up Melanoma (One Cell at a Time)
Meet Aditi Sahu, a post-doctoral fellow at Memorial Sloan Kettering Cancer Center, and MRA Dermatology Research Fellow. Learn about her work and MRA's Dermatology Fellowship Award Program.
Putting Healthy Skin First - L’Oréal Active Cosmetics Division & MRA Strengthen Longstanding L’Oréal and MRA Partnership
Some partnerships just make sense. For example, L’Oréal-owned SkinCeuticals, CeraVe and La Roche-Posay apart of the L’Oreal Active Cosmetics Division and MRA both share a mission and ethos for promoting healthy skin. It is no surprise that the two are longtime partners in the fight against melanoma. In fact, these brands and MRA have just announced an expanded partnership just in time for Melanoma Awareness Month.
Keeping You Connected to the Melanoma Community
With the launch of the brand-new Inspire App, the Melanoma > Exchange community is getting even better. Available for iPhone and iPad – the app was designed from the ground up to make connecting and sharing even easier and as mobile as you are.
MRA is Raising the Treatment Bar
We have made unprecedented progress that is transforming what it means to be diagnosed with melanoma. Today, we have more treatment options than ever before—in fact 12 new options have earned FDA approval since MRA's founding. But, it's still not enough.
SPORE Grants: Putting Collaboration Front & Center
In medicine, sometimes the biggest and most game-changing advancements come from a single person – who through tireless work – arrives at a true ‘eureka’ moment. This ‘go it alone’ concept is not only reinforced through television and movies, it’s also bolstered in the way the medical community makes research...
Treating Melanoma Patients Before Surgery
Over 90% of patients who have their tumors surgically removed will never see their tumors come back or spread to other sites, but is there a way to prevent recurrence in those patients that will eventually go on to relapse? One approach currently being tested in clinical trials, termed neoadjuvant therapy, is to treat early stage patients with targeted or immunotherapy before surgical removal of their tumor.
Highlights from the 2019 Scientific Retreat
Over the course of three days, MRA convened over 300 people from across the melanoma research community: patients, doctors, researchers, industry, and government. Participants discussed everything from new treatment approaches such as RNA-based vaccines, strategies to fight back against treatment resistance, and hurdles to testing neo-adjuvant therapies in melanoma.